Literature DB >> 24817054

Buprenorphine and nor-buprenorphine levels in head hair samples from former heroin users under Suboxone® treatment.

Stamatis Belivanis1, Manolis N Tzatzarakis, Elena Vakonaki, Leda Kovatsi, Mary Mantsi, Athanasios Alegakis, Matthaios P Kavvalakis, Dionisios Vynias, Aristidis M Tsatsakis.   

Abstract

In the current study, buprenorphine (BUP) and its major metabolite, nor-buprenorphine (NBUP), were determined in hair samples from former heroin users following Suboxone® treatment. Hair samples from 36 subjects were analyzed. The drugs of interest were isolated from hair by solid-liquid extraction with methanol and were determined by liquid chromatography-mass spectrometry, using an electrospray ionization interface. The analytical parameters of the method (such as linearity, limits of quantification, recovery, accuracy, and precision) were determined. The inter-quartile range of BUP levels was from 11.4 to 37.4 pg/mg (mean value 56.6 pg/mg) for the proximal hair segment, from 5.8 to 43.3 pg/mg for the middle hair segment (mean value 25.3 pg/mg), while a range from 4.3 to 33.9 pg/mg (mean value 105.2 pg/mg) for the distant to the root hair segment was determined. For NBUP the corresponding inter-quartile range was from 27.0 to 147.6 for the proximal segment (mean value 95.4 pg/mg), from 21.5 to 164.7 pg/mg for the middle segment (mean value 102.0 pg/mg) and from 20.4 to 103.6 pg/mg for the distant segment (mean value 156.8 pg/mg). The mean BUP/NBUP concentration ratio was 0.5. The daily dose of Suboxone® correlated significantly with BUP and NBUP levels in hair (p = 0.001 and p = 0.023) as well as with the BUP/NBUP ratio (p = 0.010). No significant correlation was found between the levels of BUP and NBUP and the duration of Suboxone® administration. The developed and validated method was successfully used for the determination of BUP and NBUP in hair samples collected from former heroin users under Suboxone® treatment.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  LC-ESI-MS; Suboxone®; buprenorphine; hair; nor-buprenorphine

Mesh:

Substances:

Year:  2014        PMID: 24817054     DOI: 10.1002/dta.1611

Source DB:  PubMed          Journal:  Drug Test Anal        ISSN: 1942-7603            Impact factor:   3.345


  3 in total

Review 1.  An overview of available drugs for management of opioid abuse during pregnancy.

Authors:  Jillian Laslo; Jon-Michael Brunner; Daniel Burns; Emily Butler; Autumn Cunningham; Ryan Killpack; Courtney Pyeritz; Kimberly Rinard; Jennifer Childers; Joseph Horzempa
Journal:  Matern Health Neonatol Perinatol       Date:  2017-02-10

2.  Intravenous buprenorphine/naloxone and concomitant oral pregabalin misuse: a case report.

Authors:  Burak Kulaksızoğlu; Hüseyin Kara; Berkan Bodur; Murat Kuloğlu
Journal:  Neuropsychiatr Dis Treat       Date:  2018-11-09       Impact factor: 2.570

Review 3.  Worldwide legislative challenges related to psychoactive drugs.

Authors:  Carolina Negrei; Bianca Galateanu; Miriana Stan; Cristian Balalau; Mircea Lucian Bogdan Dumitru; Eren Ozcagli; Concettina Fenga; Leda Kovatsi; Domniki Fragou; Aristidis Tsatsakis
Journal:  Daru       Date:  2017-06-02       Impact factor: 3.117

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.